{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T02:00:57Z","timestamp":1792461657203,"version":"4.5.0"},"reference-count":81,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Dermatology"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Janus kinase inhibitors (JAKis) have revolutionized the management of moderate\u2010to\u2010severe atopic dermatitis (AD). Although agents approved by the United States Food and Drug Administration (FDA), such as upadacitinib and abrocitinib, are widely used, and baricitinib and ivarmacitinib are under investigation, direct head\u2010to\u2010head randomized clinical trials (RCTs) comparing these agents are lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Our aim was to rank the short\u2010term efficacy of four oral JAKis, upadacitinib (15\/30\u2009mg), abrocitinib (100\/200\u2009mg), baricitinib (2\/4\u2009mg), and ivarmacitinib (4\/8\u2009mg), in moderate\u2010to\u2010severe AD using a Bayesian Network Meta\u2010Analysis (BNMA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Conducted per PRISMA 2020 guidelines and registered in PROSPERO (CRD420251116775), this study systematically reviewed phase 2 and 3 RCTs evaluating JAKi monotherapy in adults with moderate\u2010to\u2010severe AD. Primary endpoints included: (1) \u2265\u200975% improvement in Eczema Area and Severity Index (EASI\u201075), (2) Investigator's Global Assessment (IGA\u2010\n                      <jats:sc>AD<\/jats:sc>\n                      0\/1), and (3) \u2265\u20094\u2010point reduction in itch numeric rating scale (Itch NRS) at 12\u201316\u2009weeks. Bayesian hierarchical modeling estimated odds ratios (ORs) with 95% credible intervals (CrIs), and surface under the cumulative ranking curve (SUCRA) probabilities defined the treatment hierarchy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Nine RCTs (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20094261) were included. Upadacitinib 30\u2009mg demonstrated the greatest efficacy across all endpoints, EASI\u201075 (OR\u2009=\u200912.3; 95% CrI 7.9\u201318.7), IGA\u2010\n                      <jats:sc>AD<\/jats:sc>\n                      0\/1 (OR\u2009=\u200918.9; 95% CrI 12.0\u201329.7), and Itch NRS (OR\u2009=\u200911.1; 95% CrI 7.2\u201317.5), followed by upadacitinib 15\u2009mg, abrocitinib 200\u2009mg, and ivarmacitinib 8\u2009mg. Baricitinib 2\u2009mg and 4\u2009mg consistently ranked lowest. SUCRA values confirmed upadacitinib 30\u2009mg as the top performer (97%\u201398%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Among oral JAKis, upadacitinib 30\u2009mg, followed by upadacitinib 15\u2009mg, achieved the most consistent short\u2010term efficacy, providing superior skin clearance and itch relief. Abrocitinib 200\u2009mg and ivarmacitinib 8\u2009mg showed intermediate benefits, whereas baricitinib displayed modest effects. These findings support a provisional efficacy preference for upadacitinib in managing moderate\u2010to\u2010severe AD unresponsive to biologic or topical therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ijd.70228","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T14:17:41Z","timestamp":1767622661000},"page":"1395-1409","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Upadacitinib Leads in Efficacy: A Bayesian Network Meta\u2010Analysis of Four\n                    <scp>JAK<\/scp>\n                    Inhibitors in Moderate\u2010To\u2010Severe Atopic Dermatitis"],"prefix":"10.1111","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-7345-2856","authenticated-orcid":false,"given":"Arya","family":"Babul","sequence":"first","affiliation":[{"name":"West Career &amp; Technical Academy, and Society for Awareness of Neglected Diseases  Las Vegas Nevada USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0772-2570","authenticated-orcid":false,"given":"Devina","family":"Mehta","sequence":"additional","affiliation":[{"name":"General, Surgical, and Cosmetic Dermatology Thomas Dermatology  Las Vegas Nevada USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3463-3311","authenticated-orcid":false,"given":"Yssra","family":"Soliman","sequence":"additional","affiliation":[{"name":"General, Surgical, and Cosmetic Dermatology Thomas Dermatology  Las Vegas Nevada USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5017-3976","authenticated-orcid":false,"given":"Momina","family":"Hussain","sequence":"additional","affiliation":[{"name":"Genomics Department Chinese Academy of Tropical Agriculture Sciences  Sanya China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5798-1892","authenticated-orcid":false,"given":"Najib","family":"Babul","sequence":"additional","affiliation":[{"name":"Cinergen LLC  Las Vegas Nevada USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"issue":"8","key":"e_1_2_9_2_1","first-page":"S115","article-title":"Overview of Atopic Dermatitis","volume":"23","author":"Avena\u2010Woods C.","year":"2017","journal-title":"American Journal of Managed Care"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1159\/000370220"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljaf411"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1089\/derm.2025.0021"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18168"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2014.325"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/der.0000000000000486"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19500"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346\u20108138.70004"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555\u2010016\u20100170\u20101"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265\u2010020\u201001335\u20107"},{"key":"e_1_2_9_13_1","unstructured":"US Food and Drug Administration \u201cRINVOQ (upadacitinib) \u201daccessed October 16 2025 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/211675s004lbl.pdf."},{"key":"e_1_2_9_14_1","unstructured":"US Food and Drug Administration \u201cCIBINQOTM (abrocitinib) \u201daccessed October 16 2025 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/213871s000lbl.pdf."},{"key":"e_1_2_9_15_1","unstructured":"US Food and Drug Administration \u201cOLUMIANT (baricitinib) \u201daccessed October 16 2025 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/207924s006lbl.pdf."},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257\u2010022\u201000701\u20103"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265\u2010025\u201002202\u2010z"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555\u2010023\u201000892\u20105"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2022.43.220076"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15636"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19426"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18898"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(21)00588\u20102"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.02.028"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2025.0982"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(20)30732\u20107"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.11.025"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.2855"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.1406"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.3390\/jpm14070775"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1080\/25785826.2025.2567133"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555\u2010025\u201001357\u20107"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph18020178"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2021.1942422"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/pde.15386"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2023.2276043"},{"issue":"3","key":"e_1_2_9_37_1","first-page":"162","article-title":"Switching Between JAK Inhibitors in Patients With Atopic Dermatitis: Unanswered Questions in Daily Clinical Practice","volume":"31","author":"Mastraftsi S.","year":"2023","journal-title":"Acta Dermatovenerologica Croatica: ADC"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2025.103378"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.17895"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346\u20108138.17959"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/9781118951651"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1177\/096228020101000404"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2024.2192"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17351"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555\u2010022\u201000721\u20101"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555\u2010023\u201001000\u20103"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.14631"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.0796"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600\u20100625.2001.100102.x"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.09.062"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17744"},{"key":"e_1_2_9_53_1","unstructured":"R Core Team \u201cR: A Language and Environment for Statistical Computing \u201dR Foundation for Statistical Computing Vienna Austria 2022."},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008929526011"},{"key":"e_1_2_9_55_1","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v012.i03"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989x12458724"},{"key":"e_1_2_9_57_1","unstructured":"MRC Biostatistics Unit CU \u201cDeviance Information Criterion \u201daccessed October 16 2025 https:\/\/ams132\u2010winter17\u201001.courses.soe.ucsc.edu\/system\/files\/attachments\/DIC\u2010FAQ.pdf."},{"key":"e_1_2_9_58_1","unstructured":"Member State Coordination Group on Health Technology Assessment (HTA CG) \u201cMethodological Guideline for Quantitative Evidence Synthesis: Direct and Indirect Comparisons \u201dApril 2024 https:\/\/tinyurl.com\/y88xt8vk."},{"key":"e_1_2_9_59_1","unstructured":"Member State Coordination Group on Health Technology Assessment (HTA CG) \u201cPractical Guideline for Quantitative Evidence Synthesis: Direct and Indirect Comparisons \u201dApril 2024 https:\/\/tinyurl.com\/m3cdm5mm."},{"key":"e_1_2_9_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/1467-9868.00353"},{"key":"e_1_2_9_61_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12874\u2010015\u20100060\u20108"},{"key":"e_1_2_9_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.03.016"},{"key":"e_1_2_9_63_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898"},{"key":"e_1_2_9_64_1","doi-asserted-by":"publisher","DOI":"10.1002\/9781119536604"},{"key":"e_1_2_9_65_1","unstructured":"S.Dias N. J.Welton A. J.Sutton D. M.Caldwell G.Lu andA. E.Ades \u201cNICE DSU Technical Support Document 4: Inconsistency in Networks of Evidence Based on Randomised Controlled Trials \u201dLondon: National Institute for Health and Clinical Excellence April 2014."},{"key":"e_1_2_9_66_1","unstructured":"National Institute for Health and Care Excellence (NICE) \u201cNICE Health Technology Evaluations: The Manual Process and Methods \u201d[PMG36] 31 January 2022 last updated: 14 July 2025 https:\/\/www.nice.org.uk\/process\/pmg36."},{"key":"e_1_2_9_67_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.682547"},{"key":"e_1_2_9_68_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0319400"},{"key":"e_1_2_9_69_1","doi-asserted-by":"publisher","DOI":"10.1111\/cea.70125"},{"key":"e_1_2_9_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e22014"},{"key":"e_1_2_9_71_1","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v102.2075"},{"key":"e_1_2_9_72_1","unstructured":"Janus Kinase Inhibitors (JAKi) \u201cEMA Confirms Measures to Minimise Risk of Serious Side Effects With Janus Kinase Inhibitors for Chronic Inflammatory Disorders \u201daccessed 16 October 2025 https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/janus\u2010kinase\u2010inhibitors\u2010jaki."},{"key":"e_1_2_9_73_1","unstructured":"Janus Kinase (JAK) Inhibitors: Drug Safety Communication \u201cFDA Requires Warnings About Increased Risk of Serious Heart\u2010Related Events Cancer Blood Clots and Death \u201daccesses 16 October 2025 https:\/\/www.fda.gov\/safety\/medical\u2010product\u2010safety\u2010information\/janus\u2010kinase\u2010jak\u2010inhibitors\u2010drug\u2010safety\u2010communication\u2010fda\u2010requires\u2010warnings\u2010about\u2010increased\u2010risk."},{"key":"e_1_2_9_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.08.102"},{"key":"e_1_2_9_75_1","unstructured":"National Medical Products Administration (NMPA) \u201cIvarmacitinib Sulfate Tablets (\u827e\u901f\u8fbe) \u2014 Approval No. H20250008 \u201dBeijing: NMPA [in Chinese] 2025 https:\/\/www.nmpa.gov.cn\/datasearch\/home\u2010index.html."},{"key":"e_1_2_9_76_1","unstructured":"S.Dias N. J.Welton A. J.Sutton andA. E.Ades \u201cNICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta\u2010Analysis of Randomised Controlled Trials \u201dLondon: National Institute for Health and Clinical Excellence 2014."},{"key":"e_1_2_9_77_1","unstructured":"S.Dias A. J.Sutton N. J.Welton andA. E.Ades \u201cHeterogeneity: Subgroups Meta\u2010Regression Bias and Bias\u2010Adjustment \u201dLondon: National Institute for Health and Clinical Excellence 2012."},{"key":"e_1_2_9_78_1","doi-asserted-by":"publisher","DOI":"10.3390\/cimb47080659"},{"key":"e_1_2_9_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2025.04.042"},{"key":"e_1_2_9_80_1","doi-asserted-by":"publisher","DOI":"10.1093\/jimmun\/vkaf049"},{"key":"e_1_2_9_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2025.06.020"},{"key":"e_1_2_9_82_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2019380"}],"container-title":["International Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.70228","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ijd.70228","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.70228","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T11:04:21Z","timestamp":1780657461000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijd.70228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":81,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1111\/ijd.70228"],"URL":"https:\/\/doi.org\/10.1111\/ijd.70228","archive":["Portico"],"relation":{},"ISSN":["0011-9059","1365-4632"],"issn-type":[{"value":"0011-9059","type":"print"},{"value":"1365-4632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]},"assertion":[{"value":"2025-10-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}